By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Incyte Corporation 

Experimental Station
Route 141 & Henry Clay Road, Building E336
Wilmington  Delaware  19880  U.S.A.
Phone: 302-498-6700 Fax: 302-425-2750


Company News
Incyte Corporation (INCY) Appoints David Gryska As Executive Vice President And Chief Financial Officer 10/17/2014 8:26:12 AM
Incyte Corporation (INCY) To Report Third Quarter 2014 Financial Results On October 30 10/15/2014 9:11:52 AM
Incyte Corporation (INCY) Pockets $60 Million Milestone Payment From Novartis AG (NVS) 10/2/2014 6:21:50 AM
Incyte Corporation (INCY) To Present At The 21st Annual Biocentury NewsMakers Conference 9/9/2014 9:34:23 AM
Join Incyte Corporation (INCY) And Others To Raise Awareness Of Rare Blood Cancers Called Myeloproliferative Neoplasms (MPNS) And Honor MPN Heroes 9/8/2014 10:44:09 AM
Incyte Corporation (INCY), Novartis AG (NVS)’ New Drug Helps Some Bald Patients Regrow Hair 8/18/2014 6:42:01 AM
Incyte Corporation (INCY) Release: FDA Accepts Supplemental New Drug Application For Jakafi® (Ruxolitinib) And Priority Review Granted 8/5/2014 10:03:59 AM
Incyte Corporation (INCY) Reports 2014 Second-Quarter Financial Results And Updates Shareholders On Key Clinical Programs 7/31/2014 10:39:45 AM
Incyte Corporation (INCY) Partners With Genentech (RHHBY) To Help With Cancer Immunotherapy Trials 7/30/2014 8:02:41 AM
Incyte Corporation (INCY) Release: Jakafi® (ruxolitinib) Product Label Expanded To Include Overall Survival Data And Additional Safety And Dosing Information 7/28/2014 8:49:58 AM